Yahoo Finance

Cofactor Genomics, Inc. Announces CEO Transition in Preparation for Accelerated Commercial Growth and Increased Patient Access for OncoPrism, its Medicare Approved ...

Jarret Glasscock, founder and CEO, transitions to Chief Technology Officer (CTO), Board Member, and President ST. LOUIS, January 08, 2025--(BUSINESS WIRE)--Cofactor Genomics, Inc., a commercial-stage ...
Business Wire

Cofactor Genomics expands clinical use of OncoPrism, as their AI enabled RNA test achieves national clinical validation after predicting immunotherapy response in Lung Cancer ...

ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced today the validation and launch of OncoPrism ®-NSCLC, an ...
C&EN

Artificial cofactor system sustains central metabolism in bacteria

Many enzymes require cofactors such as nicotinamide adenosine dinucleotide (NAD +) or nicotinamide adenosine dinucleotide phosphate (NADP +) to shuttle electrons between reactions. Artificial redox ...
Yahoo Finance

Cofactor Genomics Presents Breakthrough Work Combining RNA and AI to bring Precision Medicine to Immunotherapy at RNA Society’s 30th Annual Meeting

SAN DIEGO, May 30, 2025--(BUSINESS WIRE)--Cofactor Genomics announced the latest validation results for OncoPrism ®, Cofactor’s breakthrough RNA-based diagnostic approach at the RNA Society’s 30th ...
Business Wire

Cofactor Genomics Announces the Expansion of OncoPrism into Colorectal, Breast, Bladder, and Kidney Cancer

ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics announced today OncoPrism for colorectal, breast, bladder, and kidney cancer. This announcement follows recent Medicare coverage of the OncoPrism ...